pSivida is a drug delivery company committed to the biomedical sector, with a primary focus on ophthalmology and oncology. pSivida has two products approved by the Food and Drug Administration (FDA): Retisert(R) to treat uveitis and Vitrasert(R) for treating AIDS-related cytomegalovirus (CMV) retinitis.
pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. pSivida has one product in fully recruited Phase III clinical trials: Iluvien(TM), which delivers fluocinolone acetonide (FA) for the treatment of diabetic macular edema (DME), formerly known as Medidur FA for DME. pSivida has licensed certain drug delivery technology to Alimera Sciences, Inc. for the development of Iluvien and certain other ophthalmic products. pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. under which Pfizer may develop additional ophthalmic products.
Psivida Limited
ASX:PVA ISIN:AU000000PSD7
News
Drug delivery company pSivida Corp (NASDAQ:PSDV)(ASX:PVA) today announced that a clinical trial has begun using its MedidurTM delivery technology to treat a form of dry-Age related Macular Degeneration (dry-AMD).
The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.
###
10,120 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 15) (Last 30 Days: 52) (Since Published: 5137)